CN117062611A - 嵌合抗原受体（car）构建体和表达car构建体的nk细胞 - Google Patents

Info

Publication number

CN117062611A

CN117062611A CN202280024474.2A CN202280024474A CN117062611A CN 117062611 A CN117062611 A CN 117062611A CN 202280024474 A CN202280024474 A CN 202280024474A CN 117062611 A CN117062611 A CN 117062611A

Authority

CN

China

Prior art keywords

polypeptide

seq

domain

amino acid

cell

Prior art date

2021-01-26

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims description 306
• 210000000822 natural killer cell Anatomy 0.000 title claims description 126
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 521
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 457
• 229920001184 polypeptide Polymers 0.000 claims abstract description 439
• 230000003834 intracellular effect Effects 0.000 claims abstract description 135
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 90
• 239000013598 vector Substances 0.000 claims abstract description 82
• 102000040430 polynucleotide Human genes 0.000 claims abstract description 67
• 108091033319 polynucleotide Proteins 0.000 claims abstract description 67
• 239000002157 polynucleotide Substances 0.000 claims abstract description 67
• 230000004068 intracellular signaling Effects 0.000 claims abstract description 66
• 238000000034 method Methods 0.000 claims abstract description 54
• 201000011510 cancer Diseases 0.000 claims abstract description 28
• 208000035473 Communicable disease Diseases 0.000 claims abstract description 18
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 213
• 230000027455 binding Effects 0.000 claims description 203
• 210000004027 cell Anatomy 0.000 claims description 197
• 239000000427 antigen Substances 0.000 claims description 112
• 102000036639 antigens Human genes 0.000 claims description 112
• 108091007433 antigens Proteins 0.000 claims description 112
• 108010076504 Protein Sorting Signals Proteins 0.000 claims description 99
• 230000031146 intracellular signal transduction Effects 0.000 claims description 97
• 108091008877 NK cell receptors Proteins 0.000 claims description 90
• 102000010648 Natural Killer Cell Receptors Human genes 0.000 claims description 90
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 87
• 102000004127 Cytokines Human genes 0.000 claims description 73
• 108090000695 Cytokines Proteins 0.000 claims description 73
• 239000003550 marker Substances 0.000 claims description 62
• 108090000623 proteins and genes Proteins 0.000 claims description 51
• 102000035181 adaptor proteins Human genes 0.000 claims description 50
• 108091005764 adaptor proteins Proteins 0.000 claims description 50
• 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 45
• -1 ifnγ Proteins 0.000 claims description 44
• 102100029197 SLAM family member 6 Human genes 0.000 claims description 43
• 239000012634 fragment Substances 0.000 claims description 42
• 239000012528 membrane Substances 0.000 claims description 42
• 150000007523 nucleic acids Chemical class 0.000 claims description 41
• 230000019491 signal transduction Effects 0.000 claims description 41
• 102100038077 CD226 antigen Human genes 0.000 claims description 40
• 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims description 40
• 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 39
• 239000000203 mixture Substances 0.000 claims description 39
• 108091008034 costimulatory receptors Proteins 0.000 claims description 38
• 230000014509 gene expression Effects 0.000 claims description 35
• 102000005962 receptors Human genes 0.000 claims description 34
• 108020003175 receptors Proteins 0.000 claims description 34
• 102000004169 proteins and genes Human genes 0.000 claims description 32
• 125000006850 spacer group Chemical group 0.000 claims description 32
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 26
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 24
• 241000713666 Lentivirus Species 0.000 claims description 24
• 239000003814 drug Substances 0.000 claims description 24
• 230000004913 activation Effects 0.000 claims description 21
• 102000003812 Interleukin-15 Human genes 0.000 claims description 20
• 108090000172 Interleukin-15 Proteins 0.000 claims description 20
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 19
• 108010074108 interleukin-21 Proteins 0.000 claims description 19
• 230000001225 therapeutic effect Effects 0.000 claims description 19
• 102100030704 Interleukin-21 Human genes 0.000 claims description 18
• 102100029198 SLAM family member 7 Human genes 0.000 claims description 16
• 230000001965 increasing effect Effects 0.000 claims description 16
• 102000039446 nucleic acids Human genes 0.000 claims description 16
• 108020004707 nucleic acids Proteins 0.000 claims description 16
• 230000000694 effects Effects 0.000 claims description 15
• 108010073816 IgE Receptors Proteins 0.000 claims description 14
• 102000009438 IgE Receptors Human genes 0.000 claims description 14
• 210000002865 immune cell Anatomy 0.000 claims description 14
• 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 13
• 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 12
• 230000003612 virological effect Effects 0.000 claims description 12
• 230000011664 signaling Effects 0.000 claims description 11
• SAZUGELZHZOXHB-UHFFFAOYSA-N acecarbromal Chemical compound CCC(Br)(CC)C(=O)NC(=O)NC(C)=O SAZUGELZHZOXHB-UHFFFAOYSA-N 0.000 claims description 10
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 10
• 208000015181 infectious disease Diseases 0.000 claims description 10
• 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims description 9
• 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 9
• 230000003213 activating effect Effects 0.000 claims description 9
• 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 8
• 230000009089 cytolysis Effects 0.000 claims description 8
• 230000004069 differentiation Effects 0.000 claims description 8
• 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 7
• 230000001472 cytotoxic effect Effects 0.000 claims description 7
• 229940124597 therapeutic agent Drugs 0.000 claims description 7
• 241000894006 Bacteria Species 0.000 claims description 6
• 108010037274 Member 9 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 claims description 6
• 206010039491 Sarcoma Diseases 0.000 claims description 6
• 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 6
• 231100000433 cytotoxic Toxicity 0.000 claims description 6
• 239000003937 drug carrier Substances 0.000 claims description 6
• 239000002773 nucleotide Substances 0.000 claims description 6
• 125000003729 nucleotide group Chemical group 0.000 claims description 6
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 5
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
• 102000001398 Granzyme Human genes 0.000 claims description 5
• 108060005986 Granzyme Proteins 0.000 claims description 5
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 5
• 201000001441 melanoma Diseases 0.000 claims description 5
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
• 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 4
• 206010060862 Prostate cancer Diseases 0.000 claims description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
• 241000700605 Viruses Species 0.000 claims description 3
• 210000000581 natural killer T-cell Anatomy 0.000 claims description 3
• 206010061424 Anal cancer Diseases 0.000 claims description 2
• 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
• 208000035143 Bacterial infection Diseases 0.000 claims description 2
• 206010005003 Bladder cancer Diseases 0.000 claims description 2
• 206010005949 Bone cancer Diseases 0.000 claims description 2
• 208000018084 Bone neoplasm Diseases 0.000 claims description 2
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
• 206010006187 Breast cancer Diseases 0.000 claims description 2
• 208000026310 Breast neoplasm Diseases 0.000 claims description 2
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
• 206010009944 Colon cancer Diseases 0.000 claims description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
• 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
• 208000017604 Hodgkin disease Diseases 0.000 claims description 2
• 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
• 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
• 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 2
• 206010027406 Mesothelioma Diseases 0.000 claims description 2
• 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
• 208000034578 Multiple myelomas Diseases 0.000 claims description 2
• 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
• 206010033128 Ovarian cancer Diseases 0.000 claims description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
• 206010038389 Renal cancer Diseases 0.000 claims description 2
• 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
• 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
• 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
• 206010057644 Testis cancer Diseases 0.000 claims description 2
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
• 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
• 206010047741 Vulval cancer Diseases 0.000 claims description 2
• 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
• 201000005188 adrenal gland cancer Diseases 0.000 claims description 2
• 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
• 201000011165 anus cancer Diseases 0.000 claims description 2
• 208000021780 appendiceal neoplasm Diseases 0.000 claims description 2
• 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
• 201000010881 cervical cancer Diseases 0.000 claims description 2
• 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
• 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 2
• 201000010175 gallbladder cancer Diseases 0.000 claims description 2
• 206010017758 gastric cancer Diseases 0.000 claims description 2
• 208000003884 gestational trophoblastic disease Diseases 0.000 claims description 2
• 201000010536 head and neck cancer Diseases 0.000 claims description 2
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
• 201000002313 intestinal cancer Diseases 0.000 claims description 2
• 201000010982 kidney cancer Diseases 0.000 claims description 2
• 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
• 208000032839 leukemia Diseases 0.000 claims description 2
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
• 201000007270 liver cancer Diseases 0.000 claims description 2
• 208000014018 liver neoplasm Diseases 0.000 claims description 2
• 201000005202 lung cancer Diseases 0.000 claims description 2
• 208000020816 lung neoplasm Diseases 0.000 claims description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
• 201000011519 neuroendocrine tumor Diseases 0.000 claims description 2
• 201000002528 pancreatic cancer Diseases 0.000 claims description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
• 208000037968 sinus cancer Diseases 0.000 claims description 2
• 201000000849 skin cancer Diseases 0.000 claims description 2
• 201000011096 spinal cancer Diseases 0.000 claims description 2
• 208000014618 spinal cord cancer Diseases 0.000 claims description 2
• 201000011549 stomach cancer Diseases 0.000 claims description 2
• 201000003120 testicular cancer Diseases 0.000 claims description 2
• 201000002510 thyroid cancer Diseases 0.000 claims description 2
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
• 206010046766 uterine cancer Diseases 0.000 claims description 2
• 206010046885 vaginal cancer Diseases 0.000 claims description 2
• 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
• 201000005102 vulva cancer Diseases 0.000 claims description 2
• 102000011769 Member 9 Tumor Necrosis Factor Receptor Superfamily Human genes 0.000 claims 3
• 102000002755 Natural Cytotoxicity Triggering Receptor 1 Human genes 0.000 claims 3
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
• 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
• 101150033527 TNF gene Proteins 0.000 claims 1
• 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
• 238000005516 engineering process Methods 0.000 abstract description 12
• 208000037765 diseases and disorders Diseases 0.000 abstract description 2
• 230000006870 function Effects 0.000 description 82
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 76
• 150000001413 amino acids Chemical class 0.000 description 60
• 235000001014 amino acid Nutrition 0.000 description 59
• 230000001086 cytosolic effect Effects 0.000 description 46
• 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 43
• 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 43
• 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 37
• 108091028043 Nucleic acid sequence Proteins 0.000 description 27
• 238000003776 cleavage reaction Methods 0.000 description 26
• 235000018102 proteins Nutrition 0.000 description 26
• 238000011282 treatment Methods 0.000 description 26
• 230000000139 costimulatory effect Effects 0.000 description 24
• 239000003153 chemical reaction reagent Substances 0.000 description 22
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
• 241000282414 Homo sapiens Species 0.000 description 18
• 230000003013 cytotoxicity Effects 0.000 description 18
• 231100000135 cytotoxicity Toxicity 0.000 description 18
• 201000010099 disease Diseases 0.000 description 18
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 16
• 229940079593 drug Drugs 0.000 description 16
• 208000024891 symptom Diseases 0.000 description 16
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 16
• 210000000170 cell membrane Anatomy 0.000 description 15
• 239000003446 ligand Substances 0.000 description 15
• 230000004807 localization Effects 0.000 description 15
• 238000003556 assay Methods 0.000 description 13
• 238000013270 controlled release Methods 0.000 description 12
• 230000026731 phosphorylation Effects 0.000 description 12
• 238000006366 phosphorylation reaction Methods 0.000 description 12
• 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 11
• 230000035772 mutation Effects 0.000 description 11
• 239000002243 precursor Substances 0.000 description 11
• 230000004044 response Effects 0.000 description 11
• 108020004414 DNA Proteins 0.000 description 10
• 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 10
• 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 10
• 101710154942 Interleukin-2 receptor subunit beta Proteins 0.000 description 10
• 101800001494 Protease 2A Proteins 0.000 description 10
• 101800001066 Protein 2A Proteins 0.000 description 10
• 239000002552 dosage form Substances 0.000 description 10
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
• 102100031778 SH2 domain-containing protein 1B Human genes 0.000 description 8
• 230000001580 bacterial effect Effects 0.000 description 8
• 239000012636 effector Substances 0.000 description 8
• 238000009472 formulation Methods 0.000 description 8
• 239000000546 pharmaceutical excipient Substances 0.000 description 8
• 230000001105 regulatory effect Effects 0.000 description 8
• 230000002441 reversible effect Effects 0.000 description 8
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 7
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 7
• 108091026890 Coding region Proteins 0.000 description 7
• 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 7
• 239000005089 Luciferase Substances 0.000 description 7
• 108010052285 Membrane Proteins Proteins 0.000 description 7
• 102100027720 SH2 domain-containing protein 1A Human genes 0.000 description 7
• 238000010171 animal model Methods 0.000 description 7
• 239000013604 expression vector Substances 0.000 description 7
• 239000013612 plasmid Substances 0.000 description 7
• 230000002829 reductive effect Effects 0.000 description 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 6
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 6
• 102000003886 Glycoproteins Human genes 0.000 description 6
• 108090000288 Glycoproteins Proteins 0.000 description 6
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 6
• 101000707218 Homo sapiens SH2 domain-containing protein 1B Proteins 0.000 description 6
• 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 6
• 241000701806 Human papillomavirus Species 0.000 description 6
• 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 6
• 102000018697 Membrane Proteins Human genes 0.000 description 6
• 102100034256 Mucin-1 Human genes 0.000 description 6
• 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 6
• 230000029918 bioluminescence Effects 0.000 description 6
• 238000005415 bioluminescence Methods 0.000 description 6
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
• 210000004698 lymphocyte Anatomy 0.000 description 6
• 239000006201 parenteral dosage form Substances 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 239000013603 viral vector Substances 0.000 description 6
• RJBDSRWGVYNDHL-XNJNKMBASA-N (2S,4R,5S,6S)-2-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2R,3S)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-5-amino-6-[(1S,2R)-2-[(2S,4R,5S,6S)-5-amino-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-4-hydroxyoxane-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)[C@H](O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@@H](CO)O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@H]2O)[C@H](O)[C@H]1O)[C@@H](O)\C=C\CCCCCCCCCCCCC RJBDSRWGVYNDHL-XNJNKMBASA-N 0.000 description 5
• 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 5
• 102000001301 EGF receptor Human genes 0.000 description 5
• 108060006698 EGF receptor Proteins 0.000 description 5
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 5
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 5
• 108010029485 Protein Isoforms Proteins 0.000 description 5
• 102000001708 Protein Isoforms Human genes 0.000 description 5
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 5
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 5
• 239000004480 active ingredient Substances 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 230000007017 scission Effects 0.000 description 5
• 239000000243 solution Substances 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 230000014616 translation Effects 0.000 description 5
• 210000004881 tumor cell Anatomy 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 4
• 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 4
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 4
• 102100038083 Endosialin Human genes 0.000 description 4
• BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 4
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 4
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 4
• 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 4
• 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 description 4
• 108010074328 Interferon-gamma Proteins 0.000 description 4
• 102000000588 Interleukin-2 Human genes 0.000 description 4
• 108010008707 Mucin-1 Proteins 0.000 description 4
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
• 101710083287 SLAM family member 7 Proteins 0.000 description 4
• 101710090322 Truncated surface protein Proteins 0.000 description 4
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 230000000259 anti-tumor effect Effects 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 206010052015 cytokine release syndrome Diseases 0.000 description 4
• 238000010586 diagram Methods 0.000 description 4
• 230000005714 functional activity Effects 0.000 description 4
• 229940027941 immunoglobulin g Drugs 0.000 description 4
• 230000001976 improved effect Effects 0.000 description 4
• 238000001802 infusion Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 229920001282 polysaccharide Polymers 0.000 description 4
• 239000005017 polysaccharide Substances 0.000 description 4
• 150000004804 polysaccharides Chemical class 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 102000035160 transmembrane proteins Human genes 0.000 description 4
• 108091005703 transmembrane proteins Proteins 0.000 description 4
• 230000003442 weekly effect Effects 0.000 description 4
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
• BXTJCSYMGFJEID-XMTADJHZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-[3-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-met Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C(SC[C@H](N)C(O)=O)CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 BXTJCSYMGFJEID-XMTADJHZSA-N 0.000 description 3
• KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 3
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
• 101710145634 Antigen 1 Proteins 0.000 description 3
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
• 108700012439 CA9 Proteins 0.000 description 3
• 102100038078 CD276 antigen Human genes 0.000 description 3
• 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 3
• 102000000844 Cell Surface Receptors Human genes 0.000 description 3
• 108010001857 Cell Surface Receptors Proteins 0.000 description 3
• 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 3
• 108020004705 Codon Proteins 0.000 description 3
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
• 101150029707 ERBB2 gene Proteins 0.000 description 3
• 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 3
• 101710116743 Ephrin type-A receptor 2 Proteins 0.000 description 3
• 102000010451 Folate receptor alpha Human genes 0.000 description 3
• 108050001931 Folate receptor alpha Proteins 0.000 description 3
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 102000010956 Glypican Human genes 0.000 description 3
• 108050001154 Glypican Proteins 0.000 description 3
• 108050007237 Glypican-3 Proteins 0.000 description 3
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
• 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 3
• 101000884275 Homo sapiens Endosialin Proteins 0.000 description 3
• 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 3
• 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 3
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 3
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 3
• 241000725303 Human immunodeficiency virus Species 0.000 description 3
• 102100037850 Interferon gamma Human genes 0.000 description 3
• 108010002350 Interleukin-2 Proteins 0.000 description 3
• 102100031413 L-dopachrome tautomerase Human genes 0.000 description 3
• 108010010995 MART-1 Antigen Proteins 0.000 description 3
• 102100023123 Mucin-16 Human genes 0.000 description 3
• 230000006051 NK cell activation Effects 0.000 description 3
• 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 3
• 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 3
• 108700020796 Oncogene Proteins 0.000 description 3
• 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 3
• 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 3
• 102100036735 Prostate stem cell antigen Human genes 0.000 description 3
• 101710120463 Prostate stem cell antigen Proteins 0.000 description 3
• 102000014400 SH2 domains Human genes 0.000 description 3
• 108050003452 SH2 domains Proteins 0.000 description 3
• 101710083278 SLAM family member 6 Proteins 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 101800001271 Surface protein Proteins 0.000 description 3
• 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 description 3
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
• 102100033447 T-lymphocyte surface antigen Ly-9 Human genes 0.000 description 3
• 238000010459 TALEN Methods 0.000 description 3
• 102100040247 Tumor necrosis factor Human genes 0.000 description 3
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 3
• 101710165434 Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 3
• 108091005906 Type I transmembrane proteins Proteins 0.000 description 3
• 108091005956 Type II transmembrane proteins Proteins 0.000 description 3
• 235000010443 alginic acid Nutrition 0.000 description 3
• 229920000615 alginic acid Polymers 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 229940088710 antibiotic agent Drugs 0.000 description 3
• 229960000106 biosimilars Drugs 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 230000036765 blood level Effects 0.000 description 3
• 229930195731 calicheamicin Natural products 0.000 description 3
• 230000006037 cell lysis Effects 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 239000007795 chemical reaction product Substances 0.000 description 3
• 150000001875 compounds Chemical class 0.000 description 3
• 210000004443 dendritic cell Anatomy 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 108010051081 dopachrome isomerase Proteins 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 239000002158 endotoxin Substances 0.000 description 3
• 108010072257 fibroblast activation protein alpha Proteins 0.000 description 3
• 210000005260 human cell Anatomy 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 229920006008 lipopolysaccharide Polymers 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 244000052769 pathogen Species 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 230000010076 replication Effects 0.000 description 3
• HXCHCVDVKSCDHU-PJKCJEBCSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-(ethylamino)-4-methoxyoxan-2-yl]oxy-4-hydroxy-6-[[(2s,5z,9r,13e)-9-hydroxy-12-(methoxycarbonylamino)-13-[2-(methyltrisulfanyl)ethylidene]-11-oxo-2-bicyclo[7.3.1]trideca-1(12),5-dien-3,7-diynyl]oxy]-2-m Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-PJKCJEBCSA-N 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 229960003989 tocilizumab Drugs 0.000 description 3
• 238000010361 transduction Methods 0.000 description 3
• 230000026683 transduction Effects 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• 230000005945 translocation Effects 0.000 description 3
• 229960000575 trastuzumab Drugs 0.000 description 3
• 241001430294 unidentified retrovirus Species 0.000 description 3
• 229950000815 veltuzumab Drugs 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• ZMEWRPBAQVSBBB-GOTSBHOMSA-N (2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[[2-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetyl]amino]hexanoic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 ZMEWRPBAQVSBBB-GOTSBHOMSA-N 0.000 description 2
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
• LTHJXDSHSVNJKG-UHFFFAOYSA-N 2-[2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOCCOC(=O)C(C)=C LTHJXDSHSVNJKG-UHFFFAOYSA-N 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
• 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 2
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
• 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 2
• 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 2
• 102100026402 Adhesion G protein-coupled receptor E2 Human genes 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 102100026189 Beta-galactosidase Human genes 0.000 description 2
• 108010051118 Bone Marrow Stromal Antigen 2 Proteins 0.000 description 2
• 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 description 2
• 101710188619 C-type lectin domain family 12 member A Proteins 0.000 description 2
• 101710185679 CD276 antigen Proteins 0.000 description 2
• 102100032912 CD44 antigen Human genes 0.000 description 2
• 108010058905 CD44v6 antigen Proteins 0.000 description 2
• 102100036008 CD48 antigen Human genes 0.000 description 2
• 102100029390 CMRF35-like molecule 1 Human genes 0.000 description 2
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
• 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
• 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 2
• 102000019034 Chemokines Human genes 0.000 description 2
• 108010012236 Chemokines Proteins 0.000 description 2
• 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 2
• 102100038449 Claudin-6 Human genes 0.000 description 2
• 108090000229 Claudin-6 Proteins 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• 108010092160 Dactinomycin Proteins 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 102100035079 ETS-related transcription factor Elf-3 Human genes 0.000 description 2
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 102100031507 Fc receptor-like protein 5 Human genes 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• 102100036939 G-protein coupled receptor 20 Human genes 0.000 description 2
• 101710108873 G-protein coupled receptor 20 Proteins 0.000 description 2
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 102000005720 Glutathione transferase Human genes 0.000 description 2
• 108010070675 Glutathione transferase Proteins 0.000 description 2
• SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 2
• 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 2
• 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000890604 Homo sapiens A-kinase anchor protein 4 Proteins 0.000 description 2
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
• 101000912622 Homo sapiens C-type lectin domain family 12 member A Proteins 0.000 description 2
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
• 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 2
• 101000990055 Homo sapiens CMRF35-like molecule 1 Proteins 0.000 description 2
• 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
• 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 description 2
• 101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 2
• 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 2
• 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 2
• 101000971605 Homo sapiens Kita-kyushu lung cancer antigen 1 Proteins 0.000 description 2
• 101001038321 Homo sapiens Leucine-rich repeat protein 1 Proteins 0.000 description 2
• 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 2
• 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 2
• 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 2
• 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 description 2
• 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 2
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
• 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 2
• 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 description 2
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
• 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 2
• 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 description 2
• 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 2
• 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 2
• 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 description 2
• 108060003951 Immunoglobulin Proteins 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 2
• 102100029616 Immunoglobulin lambda-like polypeptide 1 Human genes 0.000 description 2
• 101710107067 Immunoglobulin lambda-like polypeptide 1 Proteins 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
• 108010047761 Interferon-alpha Proteins 0.000 description 2
• 102000006992 Interferon-alpha Human genes 0.000 description 2
• 102000003814 Interleukin-10 Human genes 0.000 description 2
• 108090000174 Interleukin-10 Proteins 0.000 description 2
• 102000013462 Interleukin-12 Human genes 0.000 description 2
• 108010065805 Interleukin-12 Proteins 0.000 description 2
• 102000003810 Interleukin-18 Human genes 0.000 description 2
• 108090000171 Interleukin-18 Proteins 0.000 description 2
• 108010017411 Interleukin-21 Receptors Proteins 0.000 description 2
• 102100030699 Interleukin-21 receptor Human genes 0.000 description 2
• 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 2
• 102100021533 Kita-kyushu lung cancer antigen 1 Human genes 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 102100040249 Leucine-rich repeat protein 1 Human genes 0.000 description 2
• 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 2
• 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 2
• 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 2
• 102000008072 Lymphokines Human genes 0.000 description 2
• 108010074338 Lymphokines Proteins 0.000 description 2
• 102000016200 MART-1 Antigen Human genes 0.000 description 2
• 102000043129 MHC class I family Human genes 0.000 description 2
• 108091054437 MHC class I family Proteins 0.000 description 2
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
• 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
• 229930126263 Maytansine Natural products 0.000 description 2
• 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
• 102000000440 Melanoma-associated antigen Human genes 0.000 description 2
• 108050008953 Melanoma-associated antigen Proteins 0.000 description 2
• 102000003735 Mesothelin Human genes 0.000 description 2
• 108090000015 Mesothelin Proteins 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 101100181099 Mus musculus Klra1 gene Proteins 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 2
• 101710106341 NKG2-D type II integral membrane protein Proteins 0.000 description 2
• 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 2
• 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 2
• 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 2
• 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 2
• 102100025128 Olfactory receptor 51E2 Human genes 0.000 description 2
• 101710187841 Olfactory receptor 51E2 Proteins 0.000 description 2
• 102000015636 Oligopeptides Human genes 0.000 description 2
• 108010038807 Oligopeptides Proteins 0.000 description 2
• 102100032364 Pannexin-3 Human genes 0.000 description 2
• 101710165197 Pannexin-3 Proteins 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 102100026181 Placenta-specific protein 1 Human genes 0.000 description 2
• 108050005093 Placenta-specific protein 1 Proteins 0.000 description 2
• 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
• 102100035703 Prostatic acid phosphatase Human genes 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 2
• 102100038098 Protein-glutamine gamma-glutamyltransferase 5 Human genes 0.000 description 2
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
• 108700003853 RON Proteins 0.000 description 2
• 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 2
• 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 2
• 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
• 241000725643 Respiratory syncytial virus Species 0.000 description 2
• 102100027610 Rho-related GTP-binding protein RhoC Human genes 0.000 description 2
• 239000008156 Ringer's lactate solution Substances 0.000 description 2
• 101710097986 SH2 domain-containing protein 1B Proteins 0.000 description 2
• 102100029216 SLAM family member 5 Human genes 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 2
• 108700015968 Slam family Proteins 0.000 description 2
• 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 2
• 241000191940 Staphylococcus Species 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 101710165202 T-cell surface antigen CD2 Proteins 0.000 description 2
• 101710089528 T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
• 101710114141 T-lymphocyte surface antigen Ly-9 Proteins 0.000 description 2
• 102100036494 Testisin Human genes 0.000 description 2
• 239000004098 Tetracycline Substances 0.000 description 2
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
• 108090000253 Thyrotropin Receptors Proteins 0.000 description 2
• 102100029337 Thyrotropin receptor Human genes 0.000 description 2
• 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
• 102100021393 Transcriptional repressor CTCFL Human genes 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 108700019146 Transgenes Proteins 0.000 description 2
• 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
• 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 2
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
• 102000003425 Tyrosinase Human genes 0.000 description 2
• 108060008724 Tyrosinase Proteins 0.000 description 2
• 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 2
• 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 2
• 102000013532 Uroplakin II Human genes 0.000 description 2
• 108010065940 Uroplakin II Proteins 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
• 102100022748 Wilms tumor protein Human genes 0.000 description 2
• 101710127857 Wilms tumor protein Proteins 0.000 description 2
• 102100039490 X antigen family member 1 Human genes 0.000 description 2
• 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 229940072056 alginate Drugs 0.000 description 2
• 229960000723 ampicillin Drugs 0.000 description 2
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
• 229940049595 antibody-drug conjugate Drugs 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 108010005774 beta-Galactosidase Proteins 0.000 description 2
• 229960000397 bevacizumab Drugs 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 210000001772 blood platelet Anatomy 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000020411 cell activation Effects 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 210000002421 cell wall Anatomy 0.000 description 2
• 229960005395 cetuximab Drugs 0.000 description 2
• 102000021178 chitin binding proteins Human genes 0.000 description 2
• 108091011157 chitin binding proteins Proteins 0.000 description 2
• 230000004940 costimulation Effects 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 229960000684 cytarabine Drugs 0.000 description 2
• 229960002204 daratumumab Drugs 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 229960004497 dinutuximab Drugs 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
• 229940093471 ethyl oleate Drugs 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 229950002140 futuximab Drugs 0.000 description 2
• CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 239000005090 green fluorescent protein Substances 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 102000018358 immunoglobulin Human genes 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 108010044426 integrins Proteins 0.000 description 2
• 102000006495 integrins Human genes 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 229960000318 kanamycin Drugs 0.000 description 2
• 229930027917 kanamycin Natural products 0.000 description 2
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
• 229930182823 kanamycin A Natural products 0.000 description 2
• 230000002147 killing effect Effects 0.000 description 2
• 108010025001 leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 2
• 229950001237 lilotomab Drugs 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 230000035800 maturation Effects 0.000 description 2
• 231100000682 maximum tolerated dose Toxicity 0.000 description 2
• WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
• 229960004961 mechlorethamine Drugs 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 229950003734 milatuzumab Drugs 0.000 description 2
• 229950005674 modotuximab Drugs 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
• 229960003347 obinutuzumab Drugs 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 229950011098 pendetide Drugs 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
• 235000019419 proteases Nutrition 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
• 108010073531 rhoC GTP-Binding Protein Proteins 0.000 description 2
• 229960004641 rituximab Drugs 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
• 210000000225 synapse Anatomy 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 101150047061 tag-72 gene Proteins 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• 229960002180 tetracycline Drugs 0.000 description 2
• 229930101283 tetracycline Natural products 0.000 description 2
• 235000019364 tetracycline Nutrition 0.000 description 2
• 150000003522 tetracyclines Chemical class 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 108010058721 transglutaminase 5 Proteins 0.000 description 2
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
• 108010087967 type I signal peptidase Proteins 0.000 description 2
• BNJNAEJASPUJTO-DUOHOMBCSA-N vadastuximab talirine Chemical compound COc1ccc(cc1)C2=CN3[C@@H](C2)C=Nc4cc(OCCCOc5cc6N=C[C@@H]7CC(=CN7C(=O)c6cc5OC)c8ccc(NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CCCCCN9C(=O)C[C@@H](SC[C@H](N)C(=O)O)C9=O)C(C)C)cc8)c(OC)cc4C3=O BNJNAEJASPUJTO-DUOHOMBCSA-N 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
• FOIAQXXUVRINCI-LBAQZLPGSA-N (2S)-2-amino-6-[[4-[2-[bis(carboxymethyl)amino]-3-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]propyl]phenyl]carbamothioylamino]hexanoic acid Chemical compound N[C@@H](CCCCNC(=S)Nc1ccc(CC(CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)cc1)C(O)=O FOIAQXXUVRINCI-LBAQZLPGSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• TVIRNGFXQVMMGB-OFWIHYRESA-N (3s,6r,10r,13e,16s)-16-[(2r,3r,4s)-4-chloro-3-hydroxy-4-phenylbutan-2-yl]-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H](O)[C@@H](Cl)C=2C=CC=CC=2)C/C=C/C(=O)N1 TVIRNGFXQVMMGB-OFWIHYRESA-N 0.000 description 1
• SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
• QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
• XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
• AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
• JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
• INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 1
• RCFNNLSZHVHCEK-IMHLAKCZSA-N (7s,9s)-7-(4-amino-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C1CC([NH3+])CC(C)O1 RCFNNLSZHVHCEK-IMHLAKCZSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
• FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
• ZOHXWSHGANNQGO-DSIKUUPMSA-N 1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ZOHXWSHGANNQGO-DSIKUUPMSA-N 0.000 description 1
• BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
• BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
• QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
• CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
• YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 1
• PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
• HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
• 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
• 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
• IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
• MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
• WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
• FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
• 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
• YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
• HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
• HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 1
• 229940127148 AGS67E Drugs 0.000 description 1
• 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
• 241000714175 Abelson murine leukemia virus Species 0.000 description 1
• 102100022907 Acrosin-binding protein Human genes 0.000 description 1
• 101710107749 Acrosin-binding protein Proteins 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 101710096292 Adhesion G protein-coupled receptor E2 Proteins 0.000 description 1
• 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 description 1
• 108060003345 Adrenergic Receptor Proteins 0.000 description 1
• 102000017910 Adrenergic receptor Human genes 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
• 102100032187 Androgen receptor Human genes 0.000 description 1
• 102000009840 Angiopoietins Human genes 0.000 description 1
• 108010009906 Angiopoietins Proteins 0.000 description 1
• 102100023003 Ankyrin repeat domain-containing protein 30A Human genes 0.000 description 1
• 102100031323 Anthrax toxin receptor 1 Human genes 0.000 description 1
• 206010073360 Appendix cancer Diseases 0.000 description 1
• 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 description 1
• 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 description 1
• 102000030431 Asparaginyl endopeptidase Human genes 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
• 102100035634 B-cell linker protein Human genes 0.000 description 1
• 101710083670 B-cell linker protein Proteins 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 108091007065 BIRCs Proteins 0.000 description 1
• 229940125565 BMS-986016 Drugs 0.000 description 1
• 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
• VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
• 108060000903 Beta-catenin Proteins 0.000 description 1
• 102000015735 Beta-catenin Human genes 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 229940122361 Bisphosphonate Drugs 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 244000056139 Brassica cretica Species 0.000 description 1
• 235000003351 Brassica cretica Nutrition 0.000 description 1
• 235000003343 Brassica rupestris Nutrition 0.000 description 1
• MBABCNBNDNGODA-LTGLSHGVSA-N Bullatacin Natural products O=C1C(C[C@H](O)CCCCCCCCCC[C@@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)=C[C@H](C)O1 MBABCNBNDNGODA-LTGLSHGVSA-N 0.000 description 1
• KGGVWMAPBXIMEM-ZRTAFWODSA-N Bullatacinone Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@H]2OC(=O)[C@H](CC(C)=O)C2)CC1 KGGVWMAPBXIMEM-ZRTAFWODSA-N 0.000 description 1
• KGGVWMAPBXIMEM-JQFCFGFHSA-N Bullatacinone Natural products O=C(C[C@H]1C(=O)O[C@H](CCCCCCCCCC[C@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)C1)C KGGVWMAPBXIMEM-JQFCFGFHSA-N 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
• 108010075254 C-Peptide Proteins 0.000 description 1
• 108090000342 C-Type Lectins Proteins 0.000 description 1
• 102000003930 C-Type Lectins Human genes 0.000 description 1
• 102000002086 C-type lectin-like Human genes 0.000 description 1
• 108050009406 C-type lectin-like Proteins 0.000 description 1
• 102100023458 C-type lectin-like domain family 1 Human genes 0.000 description 1
• 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
• 238000011357 CAR T-cell therapy Methods 0.000 description 1
• 102000001902 CC Chemokines Human genes 0.000 description 1
• 108010040471 CC Chemokines Proteins 0.000 description 1
• 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
• 101710203996 CD226 antigen Proteins 0.000 description 1
• 101150013553 CD40 gene Proteins 0.000 description 1
• 108010065524 CD52 Antigen Proteins 0.000 description 1
• 102100025221 CD70 antigen Human genes 0.000 description 1
• 102100037904 CD9 antigen Human genes 0.000 description 1
• 229940038671 CDX-1401 vaccine Drugs 0.000 description 1
• 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 description 1
• 101710120600 Cancer/testis antigen 1 Proteins 0.000 description 1
• 101710120595 Cancer/testis antigen 2 Proteins 0.000 description 1
• 102000013392 Carboxylesterase Human genes 0.000 description 1
• 108010051152 Carboxylesterase Proteins 0.000 description 1
• AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 101710181340 Chaperone protein DnaK2 Proteins 0.000 description 1
• JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
• MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
• 241000193163 Clostridioides difficile Species 0.000 description 1
• 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 description 1
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 229930188224 Cryptophycin Natural products 0.000 description 1
• 108010060385 Cyclin B1 Proteins 0.000 description 1
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
• 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
• 108010072210 Cyclophilin C Proteins 0.000 description 1
• 108010077090 Cytochrome P-450 CYP1B1 Proteins 0.000 description 1
• 102000009902 Cytochrome P-450 CYP1B1 Human genes 0.000 description 1
• 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 1
• 206010050685 Cytokine storm Diseases 0.000 description 1
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
• NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 108010002156 Depsipeptides Proteins 0.000 description 1
• AUGQEEXBDZWUJY-ZLJUKNTDSA-N Diacetoxyscirpenol Chemical compound C([C@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)C)O2 AUGQEEXBDZWUJY-ZLJUKNTDSA-N 0.000 description 1
• AUGQEEXBDZWUJY-UHFFFAOYSA-N Diacetoxyscirpenol Natural products CC(=O)OCC12CCC(C)=CC1OC1C(O)C(OC(C)=O)C2(C)C11CO1 AUGQEEXBDZWUJY-UHFFFAOYSA-N 0.000 description 1
• 239000005947 Dimethoate Substances 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
• 229930193152 Dynemicin Natural products 0.000 description 1
• 101150082819 ERBB3 gene Proteins 0.000 description 1
• 229940126626 Ektomab Drugs 0.000 description 1
• 102100031334 Elongation factor 2 Human genes 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 101710144543 Endosialin Proteins 0.000 description 1
• SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
• 101001094579 Enterobacteria phage HK97 Crossover junction endodeoxyribonuclease rusA Proteins 0.000 description 1
• 102100023721 Ephrin-B2 Human genes 0.000 description 1
• 108010044090 Ephrin-B2 Proteins 0.000 description 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
• 241000214054 Equine rhinitis A virus Species 0.000 description 1
• 101150004694 Erbb4 gene Proteins 0.000 description 1
• 229930189413 Esperamicin Natural products 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 229940126611 FBTA05 Drugs 0.000 description 1
• XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
• 241000713800 Feline immunodeficiency virus Species 0.000 description 1
• 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
• 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
• 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
• 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
• 102100037362 Fibronectin Human genes 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 102000010449 Folate receptor beta Human genes 0.000 description 1
• 108050001930 Folate receptor beta Proteins 0.000 description 1
• MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
• 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
• 102000003817 Fos-related antigen 1 Human genes 0.000 description 1
• 108090000123 Fos-related antigen 1 Proteins 0.000 description 1
• 102000005668 Fusion Oncogene Proteins Human genes 0.000 description 1
• 108010084795 Fusion Oncogene Proteins Proteins 0.000 description 1
• 102100039717 G antigen 1 Human genes 0.000 description 1
• 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 description 1
• 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 1
• 102000027583 GPCRs class C Human genes 0.000 description 1
• 108091008882 GPCRs class C Proteins 0.000 description 1
• 101710113436 GTPase KRas Proteins 0.000 description 1
• 102100040510 Galectin-3-binding protein Human genes 0.000 description 1
• 101710197901 Galectin-3-binding protein Proteins 0.000 description 1
• 102000044445 Galectin-8 Human genes 0.000 description 1
• 102100039554 Galectin-8 Human genes 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000034951 Genetic Translocation Diseases 0.000 description 1
• NLKVNZUFDPWPNL-YUMQZZPRSA-N Glu-Arg-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O NLKVNZUFDPWPNL-YUMQZZPRSA-N 0.000 description 1
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
• 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
• 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
• 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
• 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
• 101710178419 Heat shock protein 70 2 Proteins 0.000 description 1
• 101710154606 Hemagglutinin Proteins 0.000 description 1
• 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
• 229920002971 Heparan sulfate Polymers 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 102000034815 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 1
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
• 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
• 101000718211 Homo sapiens Adhesion G protein-coupled receptor E2 Proteins 0.000 description 1
• 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 description 1
• 101000757191 Homo sapiens Ankyrin repeat domain-containing protein 30A Proteins 0.000 description 1
• 101000796095 Homo sapiens Anthrax toxin receptor 1 Proteins 0.000 description 1
• 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
• 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
• 101000906643 Homo sapiens C-type lectin-like domain family 1 Proteins 0.000 description 1
• 101100165850 Homo sapiens CA9 gene Proteins 0.000 description 1
• 101100112778 Homo sapiens CD247 gene Proteins 0.000 description 1
• 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 1
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
• 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
• 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
• 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 1
• 101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 description 1
• 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 description 1
• 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 1
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
• 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 1
• 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
• 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 description 1
• 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
• 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
• 101000824104 Homo sapiens High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
• 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 description 1
• 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 1
• 101001121408 Homo sapiens L-amino-acid oxidase Proteins 0.000 description 1
• 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
• 101001065550 Homo sapiens Lymphocyte antigen 6K Proteins 0.000 description 1
• 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
• 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
• 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
• 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 1
• 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
• 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 1
• 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 description 1
• 101001076732 Homo sapiens RNA-binding protein 27 Proteins 0.000 description 1
• 101001062222 Homo sapiens Receptor-binding cancer antigen expressed on SiSo cells Proteins 0.000 description 1
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
• 101000973629 Homo sapiens Ribosome quality control complex subunit NEMF Proteins 0.000 description 1
• 101000633792 Homo sapiens SLAM family member 9 Proteins 0.000 description 1
• 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
• 101001056234 Homo sapiens Sperm mitochondrial-associated cysteine-rich protein Proteins 0.000 description 1
• 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
• 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 1
• 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
• 101000738335 Homo sapiens T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 description 1
• 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
• 101100370133 Homo sapiens TPH1 gene Proteins 0.000 description 1
• 101000714168 Homo sapiens Testisin Proteins 0.000 description 1
• 101000847107 Homo sapiens Tetraspanin-8 Proteins 0.000 description 1
• 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 1
• 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
• 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
• 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 1
• 101000671653 Homo sapiens U3 small nucleolar RNA-associated protein 14 homolog A Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• 108010042653 IgA receptor Proteins 0.000 description 1
• 108010073807 IgG Receptors Proteins 0.000 description 1
• 102000009490 IgG Receptors Human genes 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
• 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 description 1
• 108010030506 Integrin alpha6beta4 Proteins 0.000 description 1
• 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
• 102100025390 Integrin beta-2 Human genes 0.000 description 1
• 102000004553 Interleukin-11 Receptors Human genes 0.000 description 1
• 108010017521 Interleukin-11 Receptors Proteins 0.000 description 1
• 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 1
• 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 1
• 108010017535 Interleukin-15 Receptors Proteins 0.000 description 1
• 102000004556 Interleukin-15 Receptors Human genes 0.000 description 1
• 102300041500 Interleukin-21 isoform 1 Human genes 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
• 241001397173 Kali <angiosperm> Species 0.000 description 1
• 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 1
• 102100026388 L-amino-acid oxidase Human genes 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 229920001491 Lentinan Polymers 0.000 description 1
• 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
• 102100032129 Lymphocyte antigen 6K Human genes 0.000 description 1
• 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
• 102100025136 Macrosialin Human genes 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 1
• 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
• 102000008840 Melanoma-associated antigen 1 Human genes 0.000 description 1
• 108050000731 Melanoma-associated antigen 1 Proteins 0.000 description 1
• 108010037255 Member 7 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 description 1
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
• IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 108010006519 Molecular Chaperones Proteins 0.000 description 1
• 102000013967 Monokines Human genes 0.000 description 1
• 108010050619 Monokines Proteins 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 101001049180 Mus musculus Killer cell lectin-like receptor subfamily B member 1C Proteins 0.000 description 1
• 101100236305 Mus musculus Ly9 gene Proteins 0.000 description 1
• 101100518997 Mus musculus Pax3 gene Proteins 0.000 description 1
• 101000868474 Mus musculus Sialoadhesin Proteins 0.000 description 1
• 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 101000668235 Mycobacterium phage L5 Gene 67 protein Proteins 0.000 description 1
• 206010051809 Myelocytosis Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
• MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
• 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 description 1
• 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
• 108091061960 Naked DNA Proteins 0.000 description 1
• 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
• 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 description 1
• 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 description 1
• 102100035488 Nectin-2 Human genes 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 101100205189 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-5 gene Proteins 0.000 description 1
• 206010029350 Neurotoxicity Diseases 0.000 description 1
• SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
• KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
• KUIFHYPNNRVEKZ-VIJRYAKMSA-N O-(N-acetyl-alpha-D-galactosaminyl)-L-threonine Chemical compound OC(=O)[C@@H](N)[C@@H](C)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O KUIFHYPNNRVEKZ-VIJRYAKMSA-N 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 206010053159 Organ failure Diseases 0.000 description 1
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
• TUVCWJQQGGETHL-UHFFFAOYSA-N PI-103 Chemical compound OC1=CC=CC(C=2N=C3C4=CC=CN=C4OC3=C(N3CCOCC3)N=2)=C1 TUVCWJQQGGETHL-UHFFFAOYSA-N 0.000 description 1
• 102000036673 PRAME Human genes 0.000 description 1
• 108060006580 PRAME Proteins 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 102100040891 Paired box protein Pax-3 Human genes 0.000 description 1
• 101710149060 Paired box protein Pax-3 Proteins 0.000 description 1
• 102100037504 Paired box protein Pax-5 Human genes 0.000 description 1
• 101710149067 Paired box protein Pax-5 Proteins 0.000 description 1
• VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 description 1
• VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 108010057150 Peplomycin Proteins 0.000 description 1
• 108010077519 Peptide Elongation Factor 2 Proteins 0.000 description 1
• 102100024968 Peptidyl-prolyl cis-trans isomerase C Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
• 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 description 1
• 102100037891 Plexin domain-containing protein 1 Human genes 0.000 description 1
• 108050009432 Plexin domain-containing protein 1 Proteins 0.000 description 1
• 102100029740 Poliovirus receptor Human genes 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 241001672814 Porcine teschovirus 1 Species 0.000 description 1
• 101710124413 Portal protein Proteins 0.000 description 1
• HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 101710176177 Protein A56 Proteins 0.000 description 1
• 102000016611 Proteoglycans Human genes 0.000 description 1
• 108010067787 Proteoglycans Proteins 0.000 description 1
• 108091034057 RNA (poly(A)) Proteins 0.000 description 1
• 102100025873 RNA-binding protein 27 Human genes 0.000 description 1
• AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 102000005435 Receptor Tyrosine Kinase-like Orphan Receptors Human genes 0.000 description 1
• 108010006700 Receptor Tyrosine Kinase-like Orphan Receptors Proteins 0.000 description 1
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
• 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
• 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
• 102100029165 Receptor-binding cancer antigen expressed on SiSo cells Human genes 0.000 description 1
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 241000712907 Retroviridae Species 0.000 description 1
• OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
• 102100022213 Ribosome quality control complex subunit NEMF Human genes 0.000 description 1
• NSFWWJIQIKBZMJ-YKNYLIOZSA-N Roridin A Chemical compound C([C@]12[C@]3(C)[C@H]4C[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)[C@@H](O)[C@H](C)CCO[C@H](\C=C\C=C/C(=O)O4)[C@H](O)C)O2 NSFWWJIQIKBZMJ-YKNYLIOZSA-N 0.000 description 1
• 102100029196 SLAM family member 9 Human genes 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
• 102100038081 Signal transducer CD24 Human genes 0.000 description 1
• 108010062314 Signaling Lymphocytic Activation Molecule Family Proteins 0.000 description 1
• 102000010841 Signaling Lymphocytic Activation Molecule Family Human genes 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 102100037253 Solute carrier family 45 member 3 Human genes 0.000 description 1
• 102000004584 Somatomedin Receptors Human genes 0.000 description 1
• 108010017622 Somatomedin Receptors Proteins 0.000 description 1
• 102100022441 Sperm surface protein Sp17 Human genes 0.000 description 1
• 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 description 1
• 101710185775 Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 108010002687 Survivin Proteins 0.000 description 1
• 102100035721 Syndecan-1 Human genes 0.000 description 1
• 108090000054 Syndecan-2 Proteins 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
• 101710156660 T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 description 1
• 102300046322 T-cell surface glycoprotein CD3 zeta chain isoform 2 Human genes 0.000 description 1
• 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
• 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
• 101150031162 TM4SF1 gene Proteins 0.000 description 1
• 229940126624 Tacatuzumab tetraxetan Drugs 0.000 description 1
• 108010017842 Telomerase Proteins 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• 102100038126 Tenascin Human genes 0.000 description 1
• 108010008125 Tenascin Proteins 0.000 description 1
• 108050003829 Testisin Proteins 0.000 description 1
• 102100032802 Tetraspanin-8 Human genes 0.000 description 1
• 241001648840 Thosea asigna virus Species 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 206010044221 Toxic encephalopathy Diseases 0.000 description 1
• 206010070863 Toxicity to various agents Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 102100034902 Transmembrane 4 L6 family member 1 Human genes 0.000 description 1
• 101710170091 Transmembrane glycoprotein NMB Proteins 0.000 description 1
• 101710081844 Transmembrane protease serine 2 Proteins 0.000 description 1
• FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
• LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 102100024971 Tryptophan 5-hydroxylase 1 Human genes 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
• 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 1
• 102100040099 U3 small nucleolar RNA-associated protein 14 homolog A Human genes 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
• 101710101493 Viral myc transforming protein Proteins 0.000 description 1
• 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
• PVNFMCBFDPTNQI-UIBOPQHZSA-N [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] acetate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 3-methylbutanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-methylpropanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] propanoate Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(C)=O)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CCC(=O)O[C@H]1CC(=O)N(C)c2cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@H](OC(=O)N3)[C@@H](C)C3O[C@@]13C)cc(OC)c2Cl.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)CC(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 PVNFMCBFDPTNQI-UIBOPQHZSA-N 0.000 description 1
• SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
• IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
• XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
• SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
• IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
• USDJGQLNFPZEON-UHFFFAOYSA-N [[4,6-bis(hydroxymethylamino)-1,3,5-triazin-2-yl]amino]methanol Chemical compound OCNC1=NC(NCO)=NC(NCO)=N1 USDJGQLNFPZEON-UHFFFAOYSA-N 0.000 description 1
• 229950005186 abagovomab Drugs 0.000 description 1
• 229960000446 abciximab Drugs 0.000 description 1
• 229950005008 abituzumab Drugs 0.000 description 1
• 229950008347 abrilumab Drugs 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
• 229950002684 aceglatone Drugs 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
• 229960004176 aclarubicin Drugs 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 229950004283 actoxumab Drugs 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 229950009084 adecatumumab Drugs 0.000 description 1
• 108010013985 adhesion receptor Proteins 0.000 description 1
• 102000019997 adhesion receptor Human genes 0.000 description 1
• 229950004955 adozelesin Drugs 0.000 description 1
• BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 1
• 229950008995 aducanumab Drugs 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 229960003227 afelimomab Drugs 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 229950008459 alacizumab pegol Drugs 0.000 description 1
• 229960000548 alemtuzumab Drugs 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229960004539 alirocumab Drugs 0.000 description 1
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
• SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 description 1
• 229960000473 altretamine Drugs 0.000 description 1
• 229950009106 altumomab Drugs 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229950001537 amatuximab Drugs 0.000 description 1
• 229960003437 aminoglutethimide Drugs 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• 229960002749 aminolevulinic acid Drugs 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 229960001220 amsacrine Drugs 0.000 description 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
• 229950006061 anatumomab mafenatox Drugs 0.000 description 1
• BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
• 229950000242 ancitabine Drugs 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 108010080146 androgen receptors Proteins 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 229950006588 anetumab ravtansine Drugs 0.000 description 1
• 229950010117 anifrolumab Drugs 0.000 description 1
• 229950005794 anrukinzumab Drugs 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000002924 anti-infective effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 239000000611 antibody drug conjugate Substances 0.000 description 1
• 230000009831 antigen interaction Effects 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
• 229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 229950003145 apolizumab Drugs 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 229950005725 arcitumomab Drugs 0.000 description 1
• 229950000847 ascrinvacumab Drugs 0.000 description 1
• 229950002882 aselizumab Drugs 0.000 description 1
• 108010055066 asparaginylendopeptidase Proteins 0.000 description 1
• 229960003852 atezolizumab Drugs 0.000 description 1
• 229950005122 atinumab Drugs 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 229950002916 avelumab Drugs 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 229950011321 azaserine Drugs 0.000 description 1
• 150000001541 aziridines Chemical class 0.000 description 1
• 210000000649 b-lymphocyte subset Anatomy 0.000 description 1
• 229950001863 bapineuzumab Drugs 0.000 description 1
• 229960004669 basiliximab Drugs 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 229950007843 bavituximab Drugs 0.000 description 1
• 229950003269 bectumomab Drugs 0.000 description 1
• 229960004965 begelomab Drugs 0.000 description 1
• 229960003270 belimumab Drugs 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 229950000321 benralizumab Drugs 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• 229950010015 bertilimumab Drugs 0.000 description 1
• 229950010559 besilesomab Drugs 0.000 description 1
• SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
• 229950008086 bezlotoxumab Drugs 0.000 description 1
• 229950001303 biciromab Drugs 0.000 description 1
• 208000026900 bile duct neoplasm Diseases 0.000 description 1
• 229950002853 bimekizumab Drugs 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 229950008548 bisantrene Drugs 0.000 description 1
• 150000004663 bisphosphonates Chemical class 0.000 description 1
• 229960005522 bivatuzumab mertansine Drugs 0.000 description 1
• 229950006844 bizelesin Drugs 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 229960003008 blinatumomab Drugs 0.000 description 1
• 229950005042 blosozumab Drugs 0.000 description 1
• 229950011350 bococizumab Drugs 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 229960001467 bortezomib Drugs 0.000 description 1
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 229960000455 brentuximab vedotin Drugs 0.000 description 1
• 229960002874 briakinumab Drugs 0.000 description 1
• 229950000025 brolucizumab Drugs 0.000 description 1
• 229950001478 brontictuzumab Drugs 0.000 description 1
• 229960005520 bryostatin Drugs 0.000 description 1
• MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
• MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000008366 buffered solution Substances 0.000 description 1
• 239000004067 bulking agent Substances 0.000 description 1
• MBABCNBNDNGODA-LUVUIASKSA-N bullatacin Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-LUVUIASKSA-N 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 229940126608 cBR96-doxorubicin immunoconjugate Drugs 0.000 description 1
• 108700002839 cactinomycin Proteins 0.000 description 1
• BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
• BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
• IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
• 229950009823 calusterone Drugs 0.000 description 1
• 229950009667 camidanlumab tesirine Drugs 0.000 description 1
• 229960001838 canakinumab Drugs 0.000 description 1
• 229950002176 caplacizumab Drugs 0.000 description 1
• 108010023376 caplacizumab Proteins 0.000 description 1
• 239000007894 caplet Substances 0.000 description 1
• 229950001178 capromab Drugs 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 229950000771 carlumab Drugs 0.000 description 1
• 229960003261 carmofur Drugs 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 229950007509 carzelesin Drugs 0.000 description 1
• BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
• 108010047060 carzinophilin Proteins 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 229960000419 catumaxomab Drugs 0.000 description 1
• 229950006754 cedelizumab Drugs 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000011748 cell maturation Effects 0.000 description 1
• 239000002458 cell surface marker Substances 0.000 description 1
• 238000002659 cell therapy Methods 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 229960003115 certolizumab pegol Drugs 0.000 description 1
• 238000003889 chemical engineering Methods 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 239000007910 chewable tablet Substances 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960001480 chlorozotocin Drugs 0.000 description 1
• ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 229950010905 citatuzumab bogatox Drugs 0.000 description 1
• 229950006647 cixutumumab Drugs 0.000 description 1
• 229950001565 clazakizumab Drugs 0.000 description 1
• 229950002334 clenoliximab Drugs 0.000 description 1
• 229950002595 clivatuzumab tetraxetan Drugs 0.000 description 1
• ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
• 229960002286 clodronic acid Drugs 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229950007906 codrituzumab Drugs 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 229950005458 coltuximab ravtansine Drugs 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 229950009735 concizumab Drugs 0.000 description 1
• 239000000562 conjugate Substances 0.000 description 1
• 108091036078 conserved sequence Proteins 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 229950001954 crenezumab Drugs 0.000 description 1
• 108010089438 cryptophycin 1 Proteins 0.000 description 1
• PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
• 108010090203 cryptophycin 8 Proteins 0.000 description 1
• PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 210000005220 cytoplasmic tail Anatomy 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 229950007409 dacetuzumab Drugs 0.000 description 1
• 229960002806 daclizumab Drugs 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 229960002482 dalotuzumab Drugs 0.000 description 1
• 229950005026 dapirolizumab pegol Drugs 0.000 description 1
• 108010048522 dapirolizumab pegol Proteins 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 229950008135 dectrekumab Drugs 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 229950007998 demcizumab Drugs 0.000 description 1
• 229950004079 denintuzumab mafodotin Drugs 0.000 description 1
• 229960001251 denosumab Drugs 0.000 description 1
• 229950002756 depatuxizumab Drugs 0.000 description 1
• 229950008925 depatuxizumab mafodotin Drugs 0.000 description 1
• 229940126610 derlotuximab biotin Drugs 0.000 description 1
• 230000002542 deteriorative effect Effects 0.000 description 1
• 229950003913 detorubicin Drugs 0.000 description 1
• 229950008962 detumomab Drugs 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 239000008356 dextrose and sodium chloride injection Substances 0.000 description 1
• 239000008355 dextrose injection Substances 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
• 229950002389 diaziquone Drugs 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
• 229930188854 dolastatin Natural products 0.000 description 1
• 229950005168 dorlimomab aritox Drugs 0.000 description 1
• ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
• 229950005454 doxifluridine Drugs 0.000 description 1
• 229960003722 doxycycline Drugs 0.000 description 1
• NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
• 229950004683 drostanolone propionate Drugs 0.000 description 1
• 229940126534 drug product Drugs 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 229960005501 duocarmycin Drugs 0.000 description 1
• VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
• 229930184221 duocarmycin Natural products 0.000 description 1
• 229950003468 dupilumab Drugs 0.000 description 1
• 229950011453 dusigitumab Drugs 0.000 description 1
• 229960002224 eculizumab Drugs 0.000 description 1
• 229950011109 edobacomab Drugs 0.000 description 1
• 229960001776 edrecolomab Drugs 0.000 description 1
• 229960000284 efalizumab Drugs 0.000 description 1
• 229950010217 eldelumab Drugs 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
• XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
• 229950002519 elgemtumab Drugs 0.000 description 1
• 229950000549 elliptinium acetate Drugs 0.000 description 1
• 229960004137 elotuzumab Drugs 0.000 description 1
• 229950002507 elsilimomab Drugs 0.000 description 1
• 229950004647 emactuzumab Drugs 0.000 description 1
• 229950004255 emibetuzumab Drugs 0.000 description 1
• 229950003048 enavatuzumab Drugs 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 229950004930 enfortumab vedotin Drugs 0.000 description 1
• JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
• 229950010213 eniluracil Drugs 0.000 description 1
• 229950000565 enlimomab pegol Drugs 0.000 description 1
• 229950004270 enoblituzumab Drugs 0.000 description 1
• 229950011487 enocitabine Drugs 0.000 description 1
• 229950007313 enokizumab Drugs 0.000 description 1
• 229950001752 enoticumab Drugs 0.000 description 1
• 229950010640 ensituximab Drugs 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229960001904 epirubicin Drugs 0.000 description 1
• 229950006414 epitumomab cituxetan Drugs 0.000 description 1
• 229930013356 epothilone Natural products 0.000 description 1
• HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
• 229950009760 epratuzumab Drugs 0.000 description 1
• 229950008579 ertumaxomab Drugs 0.000 description 1
• ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
• 229950002017 esorubicin Drugs 0.000 description 1
• LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
• 229960001842 estramustine Drugs 0.000 description 1
• 229950009569 etaracizumab Drugs 0.000 description 1
• QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 229950004912 etrolizumab Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 229950004341 evinacumab Drugs 0.000 description 1
• 229960002027 evolocumab Drugs 0.000 description 1
• 230000028023 exocytosis Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 229940093443 fanolesomab Drugs 0.000 description 1
• 229950001488 faralimomab Drugs 0.000 description 1
• 229950009929 farletuzumab Drugs 0.000 description 1
• 229950000335 fasinumab Drugs 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 229950010512 fezakinumab Drugs 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 229950002846 ficlatuzumab Drugs 0.000 description 1
• 229950008085 figitumumab Drugs 0.000 description 1
• 229950004409 firivumab Drugs 0.000 description 1
• 229950010320 flanvotumab Drugs 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 229950010043 fletikumab Drugs 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• 229960000961 floxuridine Drugs 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 108091006047 fluorescent proteins Proteins 0.000 description 1
• 102000034287 fluorescent proteins Human genes 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 150000002224 folic acids Chemical class 0.000 description 1
• 235000008191 folinic acid Nutrition 0.000 description 1
• 239000011672 folinic acid Substances 0.000 description 1
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 229950004923 fontolizumab Drugs 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 229950004356 foralumab Drugs 0.000 description 1
• 229950011078 foravirumab Drugs 0.000 description 1
• 229960004783 fotemustine Drugs 0.000 description 1
• YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• 231100000221 frame shift mutation induction Toxicity 0.000 description 1
• 230000037433 frameshift Effects 0.000 description 1
• 229950004003 fresolimumab Drugs 0.000 description 1
• 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 229950001109 galiximab Drugs 0.000 description 1
• 229940044658 gallium nitrate Drugs 0.000 description 1
• PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 description 1
• 150000002270 gangliosides Chemical class 0.000 description 1
• 229950004896 ganitumab Drugs 0.000 description 1
• 229950002508 gantenerumab Drugs 0.000 description 1
• 229950004792 gavilimomab Drugs 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229960000578 gemtuzumab Drugs 0.000 description 1
• 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 238000010362 genome editing Methods 0.000 description 1
• 229950003717 gevokizumab Drugs 0.000 description 1
• 229950002026 girentuximab Drugs 0.000 description 1
• 229950009672 glembatumumab vedotin Drugs 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229960001743 golimumab Drugs 0.000 description 1
• 229940126613 gomiliximab Drugs 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 229950010864 guselkumab Drugs 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 239000000185 hemagglutinin Substances 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
• 150000002402 hexoses Chemical group 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 125000001165 hydrophobic group Chemical group 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 208000013403 hyperactivity Diseases 0.000 description 1
• 229950010245 ibalizumab Drugs 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 229940121569 ieramilimab Drugs 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 208000013226 immunodeficiency 63 Diseases 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
• 229950008097 improsulfan Drugs 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 229950011428 indatuximab ravtansine Drugs 0.000 description 1
• 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
• 229950005015 inebilizumab Drugs 0.000 description 1
• 229940050282 inebilizumab-cdon Drugs 0.000 description 1
• 229960000598 infliximab Drugs 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 108091008042 inhibitory receptors Proteins 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 229950007937 inolimomab Drugs 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 229950001014 intetumumab Drugs 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229950003629 ipafricept Drugs 0.000 description 1
• 229960005386 ipilimumab Drugs 0.000 description 1
• 229950010939 iratumumab Drugs 0.000 description 1
• 229950007752 isatuximab Drugs 0.000 description 1
• 229940074928 isopropyl myristate Drugs 0.000 description 1
• 229950009645 istiratumab Drugs 0.000 description 1
• 229950003818 itolizumab Drugs 0.000 description 1
• 229960005435 ixekizumab Drugs 0.000 description 1
• 230000009191 jumping Effects 0.000 description 1
• 229950010828 keliximab Drugs 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 229950000518 labetuzumab Drugs 0.000 description 1
• 229950004881 labetuzumab govitecan Drugs 0.000 description 1
• CBNAAKBWBABMBY-LQCKLLCCSA-N labetuzumab-sn38 Chemical compound N([C@@H](CCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O CBNAAKBWBABMBY-LQCKLLCCSA-N 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229950000482 lampalizumab Drugs 0.000 description 1
• 108010032674 lampalizumab Proteins 0.000 description 1
• 229950002183 lebrikizumab Drugs 0.000 description 1
• 229940115286 lentinan Drugs 0.000 description 1
• 229950007439 lenzilumab Drugs 0.000 description 1
• 229950010470 lerdelimumab Drugs 0.000 description 1
• 229940121292 leronlimab Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229960001691 leucovorin Drugs 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 229950005173 libivirumab Drugs 0.000 description 1
• 229950004529 lifastuzumab vedotin Drugs 0.000 description 1
• 229950009923 ligelizumab Drugs 0.000 description 1
• 229940126616 lilotomab satetraxetan Drugs 0.000 description 1
• 229950002950 lintuzumab Drugs 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 229950011263 lirilumab Drugs 0.000 description 1
• 229950006208 lodelcizumab Drugs 0.000 description 1
• 229950000359 lokivetmab Drugs 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 229950009758 loncastuximab tesirine Drugs 0.000 description 1
• YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
• 229950008745 losoxantrone Drugs 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 229950008140 lulizumab pegol Drugs 0.000 description 1
• 229950000128 lumiliximab Drugs 0.000 description 1
• 229950010079 lumretuzumab Drugs 0.000 description 1
• 230000001320 lysogenic effect Effects 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
• 229950008612 mannomustine Drugs 0.000 description 1
• 229950001869 mapatumumab Drugs 0.000 description 1
• 229950003135 margetuximab Drugs 0.000 description 1
• 229950008083 maslimomab Drugs 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 229950008001 matuzumab Drugs 0.000 description 1
• 229950007254 mavrilimumab Drugs 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229950009246 mepitiostane Drugs 0.000 description 1
• 229960005108 mepolizumab Drugs 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 229960005558 mertansine Drugs 0.000 description 1
• ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 229950005555 metelimumab Drugs 0.000 description 1
• VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 238000012737 microarray-based gene expression Methods 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 229950002142 minretumomab Drugs 0.000 description 1
• 229950000035 mirvetuximab soravtansine Drugs 0.000 description 1
• 229960005485 mitobronitol Drugs 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 229960000350 mitotane Drugs 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• 229950003063 mitumomab Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000003032 molecular docking Methods 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 229950008897 morolimumab Drugs 0.000 description 1
• 229960001521 motavizumab Drugs 0.000 description 1
• 229950000720 moxetumomab pasudotox Drugs 0.000 description 1
• 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
• 229960003816 muromonab-cd3 Drugs 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 235000010460 mustard Nutrition 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
• 229950006780 n-acetylglucosamine Drugs 0.000 description 1
• 229950003027 nacolomab tafenatox Drugs 0.000 description 1
• 229950007708 namilumab Drugs 0.000 description 1
• 229950009793 naptumomab estafenatox Drugs 0.000 description 1
• 229950008353 narnatumab Drugs 0.000 description 1
• 229960005027 natalizumab Drugs 0.000 description 1
• 102000042628 natural cytotoxicity receptor (NCR) family Human genes 0.000 description 1
• 108091053394 natural cytotoxicity receptor (NCR) family Proteins 0.000 description 1
• 230000037125 natural defense Effects 0.000 description 1
• 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 229960002915 nebacumab Drugs 0.000 description 1
• 229960000513 necitumumab Drugs 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 229950010012 nemolizumab Drugs 0.000 description 1
• 229950009675 nerelimomab Drugs 0.000 description 1
• 229950002697 nesvacumab Drugs 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000007135 neurotoxicity Effects 0.000 description 1
• 231100000228 neurotoxicity Toxicity 0.000 description 1
• 229950010203 nimotuzumab Drugs 0.000 description 1
• 229960001420 nimustine Drugs 0.000 description 1
• VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
• JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 229960003301 nivolumab Drugs 0.000 description 1
• KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
• 229950009266 nogalamycin Drugs 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 230000030147 nuclear export Effects 0.000 description 1
• 230000012223 nuclear import Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 229960003419 obiltoxaximab Drugs 0.000 description 1
• 229950009090 ocaratuzumab Drugs 0.000 description 1
• 229950005751 ocrelizumab Drugs 0.000 description 1
• 229950010465 odulimomab Drugs 0.000 description 1
• 229960002450 ofatumumab Drugs 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 238000006384 oligomerization reaction Methods 0.000 description 1
• 229950010006 olokizumab Drugs 0.000 description 1
• 229950000846 onartuzumab Drugs 0.000 description 1
• 229950010704 opicinumab Drugs 0.000 description 1
• 229950009057 oportuzumab monatox Drugs 0.000 description 1
• 229950007283 oregovomab Drugs 0.000 description 1
• 229950009007 orticumab Drugs 0.000 description 1
• 229950002610 otelixizumab Drugs 0.000 description 1
• 229950000121 otlertuzumab Drugs 0.000 description 1
• 229950003709 oxelumab Drugs 0.000 description 1
• 229950009723 ozanezumab Drugs 0.000 description 1
• 229950007318 ozogamicin Drugs 0.000 description 1
• 229950004327 ozoralizumab Drugs 0.000 description 1
• 101710135378 pH 6 antigen Proteins 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 229950010626 pagibaximab Drugs 0.000 description 1
• 229960000402 palivizumab Drugs 0.000 description 1
• VREZDOWOLGNDPW-UHFFFAOYSA-N pancratistatine Natural products C1=C2C3C(O)C(O)C(O)C(O)C3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-UHFFFAOYSA-N 0.000 description 1
• 229960001972 panitumumab Drugs 0.000 description 1
• 229940126618 pankomab Drugs 0.000 description 1
• 229950003570 panobacumab Drugs 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 229950004260 parsatuzumab Drugs 0.000 description 1
• 229950003522 pateclizumab Drugs 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 229960002621 pembrolizumab Drugs 0.000 description 1
• 229960005570 pemtumomab Drugs 0.000 description 1
• 229940067082 pentetate Drugs 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
• 229950003180 peplomycin Drugs 0.000 description 1
• 229950005079 perakizumab Drugs 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 230000002572 peristaltic effect Effects 0.000 description 1
• 229960002087 pertuzumab Drugs 0.000 description 1
• 229950003203 pexelizumab Drugs 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 229950010773 pidilizumab Drugs 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229950010074 pinatuzumab vedotin Drugs 0.000 description 1
• 229940126620 pintumomab Drugs 0.000 description 1
• NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
• 229950001100 piposulfan Drugs 0.000 description 1
• 229950008092 placulumab Drugs 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 229950009416 polatuzumab vedotin Drugs 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 239000004417 polycarbonate Substances 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229950003486 ponezumab Drugs 0.000 description 1
• 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 229960004694 prednimustine Drugs 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 229950003700 priliximab Drugs 0.000 description 1
• 229950011407 pritoxaximab Drugs 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 108010079891 prostein Proteins 0.000 description 1
• 108020001580 protein domains Proteins 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 239000002096 quantum dot Substances 0.000 description 1
• 229950003033 quilizumab Drugs 0.000 description 1
• 229950011613 racotumomab Drugs 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 229950011639 radretumab Drugs 0.000 description 1
• 229950002786 rafivirumab Drugs 0.000 description 1
• 229950009885 ralpancizumab Drugs 0.000 description 1
• 229960002633 ramucirumab Drugs 0.000 description 1
• 229960003876 ranibizumab Drugs 0.000 description 1
• 229960002185 ranimustine Drugs 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 108010014186 ras Proteins Proteins 0.000 description 1
• 229960004910 raxibacumab Drugs 0.000 description 1
• BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
• 229960000460 razoxane Drugs 0.000 description 1
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 229950000987 refanezumab Drugs 0.000 description 1
• 229950005854 regavirumab Drugs 0.000 description 1
• 230000014493 regulation of gene expression Effects 0.000 description 1
• 210000003289 regulatory T cell Anatomy 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
• 229950005978 rinucumab Drugs 0.000 description 1
• 229950001808 robatumumab Drugs 0.000 description 1
• 229950004892 rodorubicin Drugs 0.000 description 1
• 229950010699 roledumab Drugs 0.000 description 1
• MBABCNBNDNGODA-WPZDJQSSSA-N rolliniastatin 1 Natural products O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@H]1[C@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-WPZDJQSSSA-N 0.000 description 1
• 229950010316 rontalizumab Drugs 0.000 description 1
• IMUQLZLGWJSVMV-UOBFQKKOSA-N roridin A Natural products CC(O)C1OCCC(C)C(O)C(=O)OCC2CC(=CC3OC4CC(OC(=O)C=C/C=C/1)C(C)(C23)C45CO5)C IMUQLZLGWJSVMV-UOBFQKKOSA-N 0.000 description 1
• 229950009092 rovelizumab Drugs 0.000 description 1
• 229950005374 ruplizumab Drugs 0.000 description 1
• HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
• 229950000106 samalizumab Drugs 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 229930182947 sarcodictyin Natural products 0.000 description 1
• 229950006348 sarilumab Drugs 0.000 description 1
• 229950007308 satumomab Drugs 0.000 description 1
• 229960004540 secukinumab Drugs 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 229950008834 seribantumab Drugs 0.000 description 1
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 229950003850 setoxaximab Drugs 0.000 description 1
• 229950004951 sevirumab Drugs 0.000 description 1
• 238000010008 shearing Methods 0.000 description 1
• SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
• 125000005630 sialyl group Chemical group 0.000 description 1
• 229950008684 sibrotuzumab Drugs 0.000 description 1
• 229950010077 sifalimumab Drugs 0.000 description 1
• 229950009513 simtuzumab Drugs 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 229950006094 sirukumab Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000008354 sodium chloride injection Substances 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 229950003763 sofituzumab vedotin Drugs 0.000 description 1
• 229950007874 solanezumab Drugs 0.000 description 1
• 229950011267 solitomab Drugs 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 229950006551 sontuzumab Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 229950006315 spirogermanium Drugs 0.000 description 1
• ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 229950002549 stamulumab Drugs 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 229950010708 sulesomab Drugs 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 229950001915 suvizumab Drugs 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 206010042863 synovial sarcoma Diseases 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 229950010265 tabalumab Drugs 0.000 description 1
• 229950001072 tadocizumab Drugs 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229950004218 talizumab Drugs 0.000 description 1
• 229950008160 tanezumab Drugs 0.000 description 1
• 229950001603 taplitumomab paptox Drugs 0.000 description 1
• 229950007435 tarextumab Drugs 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• 229940126625 tavolimab Drugs 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229950000864 technetium (99mtc) nofetumomab merpentan Drugs 0.000 description 1
• 229950001788 tefibazumab Drugs 0.000 description 1
• 229950008300 telimomab aritox Drugs 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• CBPNZQVSJQDFBE-HGVVHKDOSA-N temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 description 1
• 229950001289 tenatumomab Drugs 0.000 description 1
• 229950000301 teneliximab Drugs 0.000 description 1
• 229950010127 teplizumab Drugs 0.000 description 1
• 229950010259 teprotumumab Drugs 0.000 description 1
• 229950009054 tesidolumab Drugs 0.000 description 1
• 229960005353 testolactone Drugs 0.000 description 1
• BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 230000002992 thymic effect Effects 0.000 description 1
• YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
• 229950011457 tiamiprine Drugs 0.000 description 1
• 229950004742 tigatuzumab Drugs 0.000 description 1
• 229950005515 tildrakizumab Drugs 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• 229950004269 tisotumab vedotin Drugs 0.000 description 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• 229950001802 toralizumab Drugs 0.000 description 1
• 229950008836 tosatoxumab Drugs 0.000 description 1
• 229950005808 tovetumab Drugs 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 229950000835 tralokinumab Drugs 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000002463 transducing effect Effects 0.000 description 1
• 208000037918 transfusion-transmitted disease Diseases 0.000 description 1
• 238000012250 transgenic expression Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 229950010086 tregalizumab Drugs 0.000 description 1
• 229950007217 tremelimumab Drugs 0.000 description 1
• IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
• 229950001353 tretamine Drugs 0.000 description 1
• 229960004560 triaziquone Drugs 0.000 description 1
• PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
• 229930013292 trichothecene Natural products 0.000 description 1
• 150000003327 trichothecene derivatives Chemical class 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 229960001670 trilostane Drugs 0.000 description 1
• KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
• 229960001099 trimetrexate Drugs 0.000 description 1
• NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
• 229960000875 trofosfamide Drugs 0.000 description 1
• UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
• HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
• 229950003364 tucotuzumab celmoleukin Drugs 0.000 description 1
• 108700008509 tucotuzumab celmoleukin Proteins 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 230000005909 tumor killing Effects 0.000 description 1
• 229950005082 tuvirumab Drugs 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 229950009811 ubenimex Drugs 0.000 description 1
• 229950004593 ublituximab Drugs 0.000 description 1
• 229950010095 ulocuplumab Drugs 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 229960001055 uracil mustard Drugs 0.000 description 1
• 229950005972 urelumab Drugs 0.000 description 1
• 229950004362 urtoxazumab Drugs 0.000 description 1
• 229960003824 ustekinumab Drugs 0.000 description 1
• 229950003520 utomilumab Drugs 0.000 description 1
• 229950000302 vadastuximab Drugs 0.000 description 1
• 229950001694 vadastuximab talirine Drugs 0.000 description 1
• 229950001876 vandortuzumab vedotin Drugs 0.000 description 1
• 229950008718 vantictumab Drugs 0.000 description 1
• 229950000449 vanucizumab Drugs 0.000 description 1
• 229950000386 vapaliximab Drugs 0.000 description 1
• 229950001067 varlilumab Drugs 0.000 description 1
• 229950002148 vatelizumab Drugs 0.000 description 1
• 229960004914 vedolizumab Drugs 0.000 description 1
• 229950010789 vesencumab Drugs 0.000 description 1
• 229960005212 vindesine sulfate Drugs 0.000 description 1
• 229950004393 visilizumab Drugs 0.000 description 1
• 229950001212 volociximab Drugs 0.000 description 1
• 229960000237 vorinostat Drugs 0.000 description 1
• WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
• 229950003511 votumumab Drugs 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• JFCFGYGEYRIEBE-YVLHJLIDSA-N wob38vs2ni Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)S)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 JFCFGYGEYRIEBE-YVLHJLIDSA-N 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1
• 229950009002 zanolimumab Drugs 0.000 description 1
• 229950009083 ziralimumab Drugs 0.000 description 1
• 229950001346 zolimomab aritox Drugs 0.000 description 1
• 229940020965 zoloft Drugs 0.000 description 1